Hyperthermia combined with chemotherapy for patients with residual or recurrent oesophageal cancer after definitive chemoradiotherapy

Yoshihiko Maehara, Sho Nishimura, Hiroshi Saeki, Tomonori Nakanoko, Yuta Kasagi, Yasuo Tsuda, Yoko Zaitsu, Koji Ando, Yuichiro Nakashima, Y. U. Imamura, Kippei Ohgaki, Eiji Oki, Saiji Ohga, Katsumasa Nakamura, Masaru Morita

研究成果: ジャーナルへの寄稿記事

5 引用 (Scopus)

抄録

Background/Aim: Definitive chemoradiotherapy (dCRT) is frequently administered in oesophageal cancer. We carried out hyperthermochemotherapy (HCT) for residual or recurrent cases after dCRT for oesophageal cancer. The aim of this study was to elucidate the usefulness of salvage HCT for these patients. Patients and Methods: Salvage HCT after dCRT was performed in 11 patients with residual or recurrent oesophageal cancer. We used an 8-MHz radiofrequency capacitive heating system for hyperthermia. The combined chemotherapy comprised of cisplatin/5-fluorouracil, an oral fluoropyrimidine and irinotecan. Results: There were no severe adverse events caused by hyperthermia. Complete response and stable disease was achieved in three and five patients, respectively; symptoms were improved in the remaining three patients. The median survival time after HCT was 12 (range=3-88) months. Conclusion: HCT is a feasible and potent salvage therapy for patients with residual or recurrent oesophageal cancer after dCRT, unless salvage surgery is indicated.

元の言語英語
ページ(範囲)2299-2304
ページ数6
ジャーナルAnticancer research
35
発行部数4
出版物ステータス出版済み - 4 1 2015

Fingerprint

Chemoradiotherapy
Esophageal Neoplasms
Fever
Drug Therapy
irinotecan
Salvage Therapy
Fluorouracil
Heating
Cisplatin
Survival

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

これを引用

Maehara, Y., Nishimura, S., Saeki, H., Nakanoko, T., Kasagi, Y., Tsuda, Y., ... Morita, M. (2015). Hyperthermia combined with chemotherapy for patients with residual or recurrent oesophageal cancer after definitive chemoradiotherapy. Anticancer research, 35(4), 2299-2304.

Hyperthermia combined with chemotherapy for patients with residual or recurrent oesophageal cancer after definitive chemoradiotherapy. / Maehara, Yoshihiko; Nishimura, Sho; Saeki, Hiroshi; Nakanoko, Tomonori; Kasagi, Yuta; Tsuda, Yasuo; Zaitsu, Yoko; Ando, Koji; Nakashima, Yuichiro; Imamura, Y. U.; Ohgaki, Kippei; Oki, Eiji; Ohga, Saiji; Nakamura, Katsumasa; Morita, Masaru.

:: Anticancer research, 巻 35, 番号 4, 01.04.2015, p. 2299-2304.

研究成果: ジャーナルへの寄稿記事

Maehara, Y, Nishimura, S, Saeki, H, Nakanoko, T, Kasagi, Y, Tsuda, Y, Zaitsu, Y, Ando, K, Nakashima, Y, Imamura, YU, Ohgaki, K, Oki, E, Ohga, S, Nakamura, K & Morita, M 2015, 'Hyperthermia combined with chemotherapy for patients with residual or recurrent oesophageal cancer after definitive chemoradiotherapy', Anticancer research, 巻. 35, 番号 4, pp. 2299-2304.
Maehara Y, Nishimura S, Saeki H, Nakanoko T, Kasagi Y, Tsuda Y その他. Hyperthermia combined with chemotherapy for patients with residual or recurrent oesophageal cancer after definitive chemoradiotherapy. Anticancer research. 2015 4 1;35(4):2299-2304.
Maehara, Yoshihiko ; Nishimura, Sho ; Saeki, Hiroshi ; Nakanoko, Tomonori ; Kasagi, Yuta ; Tsuda, Yasuo ; Zaitsu, Yoko ; Ando, Koji ; Nakashima, Yuichiro ; Imamura, Y. U. ; Ohgaki, Kippei ; Oki, Eiji ; Ohga, Saiji ; Nakamura, Katsumasa ; Morita, Masaru. / Hyperthermia combined with chemotherapy for patients with residual or recurrent oesophageal cancer after definitive chemoradiotherapy. :: Anticancer research. 2015 ; 巻 35, 番号 4. pp. 2299-2304.
@article{9513cc3d7b564bd287728e70d7fe1bb6,
title = "Hyperthermia combined with chemotherapy for patients with residual or recurrent oesophageal cancer after definitive chemoradiotherapy",
abstract = "Background/Aim: Definitive chemoradiotherapy (dCRT) is frequently administered in oesophageal cancer. We carried out hyperthermochemotherapy (HCT) for residual or recurrent cases after dCRT for oesophageal cancer. The aim of this study was to elucidate the usefulness of salvage HCT for these patients. Patients and Methods: Salvage HCT after dCRT was performed in 11 patients with residual or recurrent oesophageal cancer. We used an 8-MHz radiofrequency capacitive heating system for hyperthermia. The combined chemotherapy comprised of cisplatin/5-fluorouracil, an oral fluoropyrimidine and irinotecan. Results: There were no severe adverse events caused by hyperthermia. Complete response and stable disease was achieved in three and five patients, respectively; symptoms were improved in the remaining three patients. The median survival time after HCT was 12 (range=3-88) months. Conclusion: HCT is a feasible and potent salvage therapy for patients with residual or recurrent oesophageal cancer after dCRT, unless salvage surgery is indicated.",
author = "Yoshihiko Maehara and Sho Nishimura and Hiroshi Saeki and Tomonori Nakanoko and Yuta Kasagi and Yasuo Tsuda and Yoko Zaitsu and Koji Ando and Yuichiro Nakashima and Imamura, {Y. U.} and Kippei Ohgaki and Eiji Oki and Saiji Ohga and Katsumasa Nakamura and Masaru Morita",
year = "2015",
month = "4",
day = "1",
language = "English",
volume = "35",
pages = "2299--2304",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "4",

}

TY - JOUR

T1 - Hyperthermia combined with chemotherapy for patients with residual or recurrent oesophageal cancer after definitive chemoradiotherapy

AU - Maehara, Yoshihiko

AU - Nishimura, Sho

AU - Saeki, Hiroshi

AU - Nakanoko, Tomonori

AU - Kasagi, Yuta

AU - Tsuda, Yasuo

AU - Zaitsu, Yoko

AU - Ando, Koji

AU - Nakashima, Yuichiro

AU - Imamura, Y. U.

AU - Ohgaki, Kippei

AU - Oki, Eiji

AU - Ohga, Saiji

AU - Nakamura, Katsumasa

AU - Morita, Masaru

PY - 2015/4/1

Y1 - 2015/4/1

N2 - Background/Aim: Definitive chemoradiotherapy (dCRT) is frequently administered in oesophageal cancer. We carried out hyperthermochemotherapy (HCT) for residual or recurrent cases after dCRT for oesophageal cancer. The aim of this study was to elucidate the usefulness of salvage HCT for these patients. Patients and Methods: Salvage HCT after dCRT was performed in 11 patients with residual or recurrent oesophageal cancer. We used an 8-MHz radiofrequency capacitive heating system for hyperthermia. The combined chemotherapy comprised of cisplatin/5-fluorouracil, an oral fluoropyrimidine and irinotecan. Results: There were no severe adverse events caused by hyperthermia. Complete response and stable disease was achieved in three and five patients, respectively; symptoms were improved in the remaining three patients. The median survival time after HCT was 12 (range=3-88) months. Conclusion: HCT is a feasible and potent salvage therapy for patients with residual or recurrent oesophageal cancer after dCRT, unless salvage surgery is indicated.

AB - Background/Aim: Definitive chemoradiotherapy (dCRT) is frequently administered in oesophageal cancer. We carried out hyperthermochemotherapy (HCT) for residual or recurrent cases after dCRT for oesophageal cancer. The aim of this study was to elucidate the usefulness of salvage HCT for these patients. Patients and Methods: Salvage HCT after dCRT was performed in 11 patients with residual or recurrent oesophageal cancer. We used an 8-MHz radiofrequency capacitive heating system for hyperthermia. The combined chemotherapy comprised of cisplatin/5-fluorouracil, an oral fluoropyrimidine and irinotecan. Results: There were no severe adverse events caused by hyperthermia. Complete response and stable disease was achieved in three and five patients, respectively; symptoms were improved in the remaining three patients. The median survival time after HCT was 12 (range=3-88) months. Conclusion: HCT is a feasible and potent salvage therapy for patients with residual or recurrent oesophageal cancer after dCRT, unless salvage surgery is indicated.

UR - http://www.scopus.com/inward/record.url?scp=84928402428&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928402428&partnerID=8YFLogxK

M3 - Article

C2 - 25862892

AN - SCOPUS:84928402428

VL - 35

SP - 2299

EP - 2304

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 4

ER -